Related Experiment Videos
Aminoglutethimide in malignant melanoma. A phase II study
S Block1, J Bonneterre, A Adenis
1Centre Oscar Lambret, BP 307-59020 Lille, France.
American Journal of Clinical Oncology
|June 1, 1992
Summary
This study found aminoglutethimide, an aromatase inhibitor, ineffective for malignant melanoma patients. The treatment was well-tolerated but showed no response in heavily pretreated individuals.
Area of Science:
- Oncology
- Endocrinology
Background:
- Steroid hormones are implicated in malignant melanoma growth.
- Aromatase activity has been detected in melanoma tissues.
Purpose of the Study:
- To evaluate the efficacy of aminoglutethimide, an aromatase inhibitor, in patients with malignant melanoma.
Main Methods:
- A phase II clinical study was conducted.
- Fifteen heavily pretreated malignant melanoma patients were enrolled.
Main Results:
- No objective responses were observed in any of the patients.
- Aminoglutethimide treatment was generally well-tolerated.
Conclusions:
- Aminoglutethimide is unlikely to be an effective treatment for malignant melanoma.
- Further investigation into hormonal therapies for melanoma may be warranted.